Cytosorbents Retained Earnings Total Equity from 2010 to 2025

CTSO Stock  USD 1.00  0.02  1.96%   
Cytosorbents Crp Retained Earnings Total Equity yearly trend continues to be very stable with very little volatility. Retained Earnings Total Equity is likely to grow to about -217.2 M this year. Retained Earnings Total Equity is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. View All Fundamentals
 
Retained Earnings Total Equity  
First Reported
2011-06-30
Previous Quarter
-261.3 M
Current Value
-267.5 M
Quarterly Volatility
77.3 M
 
Yuan Drop
 
Covid
Check Cytosorbents Crp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytosorbents Crp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 135 K or Selling General Administrative of 45.7 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.002 or PTB Ratio of 2.01. Cytosorbents financial statements analysis is a perfect complement when working with Cytosorbents Crp Valuation or Volatility modules.
  
Check out the analysis of Cytosorbents Crp Correlation against competitors.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

Latest Cytosorbents Crp's Retained Earnings Total Equity Growth Pattern

Below is the plot of the Retained Earnings Total Equity of Cytosorbents Crp over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Cytosorbents Crp's Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytosorbents Crp's overall financial position and show how it may be relating to other accounts over time.
Retained Earnings Total Equity10 Years Trend
Slightly volatile
   Retained Earnings Total Equity   
       Timeline  

Cytosorbents Retained Earnings Total Equity Regression Statistics

Arithmetic Mean(141,562,266)
Geometric Mean0.00
Coefficient Of Variation(66.42)
Mean Deviation76,380,245
Median(152,312,636)
Standard Deviation94,022,292
Sample Variance8840.2T
Range254M
R-Value(0.92)
Mean Square Error1427.2T
R-Squared0.85
Slope(18,199,985)
Total Sum of Squares132602.9T

Cytosorbents Retained Earnings Total Equity History

2025-217.2 M
2024-228.6 M
2022-254 M
2021-221.2 M
2020-196.6 M
2019-188.8 M
2018-169.5 M

About Cytosorbents Crp Financial Statements

Cytosorbents Crp investors utilize fundamental indicators, such as Retained Earnings Total Equity, to predict how Cytosorbents Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Retained Earnings Total Equity-228.6 M-217.2 M
When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:
Check out the analysis of Cytosorbents Crp Correlation against competitors.
To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.36)
Revenue Per Share
0.72
Quarterly Revenue Growth
0.066
Return On Assets
(0.28)
Return On Equity
(1.19)
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.